 BEIJING BURLINGTON, Mass.BUSINESS WIRECANbridge Pharmaceuticals, Inc. 1228.HK, a global biopharmaceutical company, with a foundation in China, committed to the research, development and commercialization of transformative therapies to treat rare diseases and oncology, announced that the first patient has been dosed in the Phase 2 part of the ongoing CAN103 Phase 12 trial in treatment-naïve ...... 